Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.
暂无分享,去创建一个
M. Kaminski | P. Ouillette | S. Malek | K. Shedden | Cheng Li | M. Talpaz | E. Peres | Lisa A Kujawski | Jinghui Li | R. Collins | Sajid Shakhan
[1] Kerby Shedden,et al. Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. , 2010, Blood.
[2] M. Dyer,et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. , 2010, Blood.
[3] C. Fegan,et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. , 2010, Blood.
[4] George A Calin,et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. , 2010, Blood.
[5] F. Nguyen‐Khac,et al. Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells. , 2010, Blood.
[6] P. Ouillette,et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. , 2010, Blood.
[7] Ronald Levy,et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.
[8] L. Ding,et al. Aggressive Chronic Lymphocytic Leukemia with Elevated Genomic Complexity Is Associated with Multiple Gene Defects in the Response to DNA Double-Strand Breaks , 2010, Clinical Cancer Research.
[9] J. Staaf,et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients , 2010, Leukemia.
[10] ONSTANZE,et al. GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .
[11] Š. Pospíšilová,et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. , 2009, Blood.
[12] Jeffrey A Jones,et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Kitzman,et al. Acquired copy number alterations in adult acute myeloid leukemia genomes , 2009, Proceedings of the National Academy of Sciences.
[14] Xavier Estivill,et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. , 2009, Blood.
[15] B. Lakshmi,et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). , 2009, Blood.
[16] D. Rossi,et al. The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness , 2009, Clinical Cancer Research.
[17] Susan O'Brien,et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. , 2008, Blood.
[18] M J S Dyer,et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease , 2009, Leukemia.
[19] T. Haferlach,et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype , 2009, Leukemia.
[20] M. McDevitt,et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. , 2008, Cancer research.
[21] N. Schmitz,et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Radich,et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Axel Benner,et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. , 2008, Blood.
[24] Sonia Jain,et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. , 2008, Blood.
[25] T. Lister,et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. , 2008, Blood.
[26] T. Shanafelt,et al. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Ogawa,et al. Molecular allelokaryotyping of early‐stage, untreated chronic lymphocytic leukemia , 2008, Cancer.
[28] M. Kaminski,et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. , 2007, Blood.
[29] M. Kaminski,et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. , 2007, Blood.
[30] J Wade Harper,et al. The DNA damage response: ten years after. , 2007, Molecular cell.
[31] R. Siebert,et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] T. Haferlach,et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping , 2007, Leukemia.
[33] A. Hagemeijer,et al. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine , 2007, Leukemia.
[34] Christopher B. Miller,et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.
[35] Jens Timmer,et al. Using High-density Snp Arrays Genome-wide Analysis of Dna Copy Number Changes and Loh in Cll , 2022 .
[36] Lisa L. Smith,et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. , 2006, Blood.
[37] T. Haferlach,et al. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. , 2006, Blood.
[38] C. Mayr,et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. , 2006, Blood.
[39] M. Andreeff,et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] N. Chiorazzi,et al. mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .
[41] J. Byrd,et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. , 2005, Blood.
[42] Cheng Li,et al. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data , 2004, Bioinform..
[43] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[44] N. Chiorazzi,et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.
[45] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.
[46] C. Fegan,et al. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. , 1995, Leukemia.
[47] A Benner,et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.
[48] B. Quesnel,et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.
[49] E. Newcomb,et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression , 1993 .
[50] G. Gaidano,et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.